| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Using the MTT assay, the impact of SR-3306 or Tat-Sab on cell viability in response to oxidative stress was determined. When H9c2 cells were treated with 100 μM H2O2/FeSO4, their survival rate was roughly 40%. However, when 500 nM SR-3306 or 500 nM SR3562 were added, the survival rate jumped to almost 90%. Furthermore, cells treated with 100 μM H2O2/FeSO4 had a vitality of 98%; in contrast, cells treated with 10 μM Tat-Sab peptide had a viability of roughly 70%. Primary human cardiomyocytes showed similar outcomes [2].
|
|---|---|
| ln Vivo |
When SR-3306 [10 mg/kg/day (sc)] was administered for 14 days, the number of tyrosine hydroxylase immunoreactive (TH+) neurons in the SNpc rose six times after the treatment compared to the control group. decreased striatal TH+ terminal loss. Rats with 6-OHDA lesions on the corresponding side were given vehicle alone (p<0.05). Moreover, SR-3306 [10 mg/kg/day (sc) for 14 days] decreased the cyclic 87% reduction caused by d-amphetamine. At day 14, SR-3306's steady-state brain levels were 347 nM, which is around two times greater than the compound's cell-based IC50. Lastly, SR-3306 [10 mg/kg/day (sc) for 14 days] decreased the number of immunoreactive neurons in the substantia nigra 2.3 times the pars compacta (SNpc) in comparison to rats treated with vehicle, according to immunohistochemistry labeling of phosphorylated c-jun (pc-jun) [1]. SR-3306 administered intraperitoneally (ip) or intracerebroventricularly (icv) decreased food intake and body weight in lean mice. Additionally, SR11935 administered ip or icv had anorexia effects comparable to those of SR3306, indicating that pan-JNK inhibition mediates some of the anorexic effects through JNK2 or JNK3. Moreover, high-fat diet-fed lean mice that get a daily intraperitoneal injection of SR-3306 for seven days are prevented from gaining weight and from eating more, and this injection modality lowers high-fat intake in diet-induced obesity (DIO) and obesity. mice[3].
|
| References |
|
| Molecular Formula |
C28H26N8O
|
|---|---|
| Molecular Weight |
490.571
|
| Exact Mass |
490.222
|
| CAS # |
1128096-91-2
|
| PubChem CID |
57519510
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
779.9±70.0 °C at 760 mmHg
|
| Flash Point |
425.5±35.7 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.712
|
| LogP |
3.75
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
700
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QDMXVKKPYBGIAS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H26N8O/c1-20-5-6-22(18-30-20)27-31-19-36(34-27)24-9-7-23(8-10-24)32-28-29-12-11-26(33-28)21-3-2-4-25(17-21)35-13-15-37-16-14-35/h2-12,17-19H,13-16H2,1H3,(H,29,32,33)
|
| Chemical Name |
N-[4-[3-(6-methylpyridin-3-yl)-1,2,4-triazol-1-yl]phenyl]-4-(3-morpholin-4-ylphenyl)pyrimidin-2-amine
|
| Synonyms |
SR-3306 SR-3306 SR-3306
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~254.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0384 mL | 10.1922 mL | 20.3845 mL | |
| 5 mM | 0.4077 mL | 2.0384 mL | 4.0769 mL | |
| 10 mM | 0.2038 mL | 1.0192 mL | 2.0384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
